[Smile]_老虎社区_美港股上老虎

Jessemyne
2021-11-22

[Smile]

iSpecimen shares surged more than 140% in early trading

iSpecimen shares surged more than 140% in early trading.iSpecimen Inc.(Nasdaq: ISPC), an online mark

iSpecimen shares surged more than 140% in early trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":875963727,"tweetId":"875963727","gmtCreate":1637594912596,"gmtModify":1637594912716,"author":{"id":3572319379588082,"idStr":"3572319379588082","authorId":3572319379588082,"authorIdStr":"3572319379588082","name":"Jessemyne","avatar":"https://static.tigerbbs.com/6252e2c2d2486e6000e4f9a349488762","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Smile]&nbsp;</span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Smile]&nbsp;</span><br></p></body></html>","text":"[Smile]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875963727","repostId":1121185868,"repostType":4,"repost":{"id":"1121185868","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637592275,"share":"https://www.laohu8.com/m/news/1121185868?lang=&edition=full","pubTime":"2021-11-22 22:44","market":"us","language":"en","title":"iSpecimen shares surged more than 140% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121185868","media":"Tiger Newspress","summary":"iSpecimen shares surged more than 140% in early trading.iSpecimen Inc.(Nasdaq: ISPC), an online mark","content":"<p>iSpecimen&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;140%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/004231075c27a5023d82afda7d30605e\" tg-width=\"865\" tg-height=\"597\" width=\"100%\" height=\"auto\"><b><a href=\"https://laohu8.com/S/ISPC\">iSpecimen Inc.</a></b>(Nasdaq: ISPC), an online marketplace for<u>human biospecimens</u>, today announced that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.</p>\n<p>The Company's work on COVID-19 began immediately after the outbreak last year when it began&nbsp;sending serum samples to the U.S. Centers for Disease Control and Prevention&nbsp;to help&nbsp;researchers monitor antibody development for possible guidance on immunity. iSpecimen provided the Centers for Disease Control and Prevention (\"CDC\") with 600 SARS-CoV-2-positive serum samples and 100 negative serum samples, mostly remnants from lab tests.</p>\n<p>In addition, iSpecimen has been contracted by other federal agencies and private companies for custom COVID-19 collections, which are often complex and complement the more immediate availability of remnant or banked samples.</p>\n<p>\"COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society's ability to contend with future outbreaks of infectious diseases,\" said&nbsp;iSpecimen Founder and CEO,Christopher Ianelli, MD, Ph.D. \"We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they're focusing on.\"</p>\n<p><b>COVID-Related Research</b></p>\n<p>In addition to the work iSpecimen has done with the CDC, iSpecimen has recently supplied hundreds of human biospecimens to ongoing COVID-19 research being conducted by&nbsp;the United Statesmilitary. The specimens, including positive SARS-CoV-2 samples and negative controls, help researchers validate COVID-19 testing platforms, understand fluctuations in patients' antibody levels, monitor contagion among close contacts, and more.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iSpecimen shares surged more than 140% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niSpecimen shares surged more than 140% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-22 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>iSpecimen&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;140%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/004231075c27a5023d82afda7d30605e\" tg-width=\"865\" tg-height=\"597\" width=\"100%\" height=\"auto\"><b><a href=\"https://laohu8.com/S/ISPC\">iSpecimen Inc.</a></b>(Nasdaq: ISPC), an online marketplace for<u>human biospecimens</u>, today announced that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.</p>\n<p>The Company's work on COVID-19 began immediately after the outbreak last year when it began&nbsp;sending serum samples to the U.S. Centers for Disease Control and Prevention&nbsp;to help&nbsp;researchers monitor antibody development for possible guidance on immunity. iSpecimen provided the Centers for Disease Control and Prevention (\"CDC\") with 600 SARS-CoV-2-positive serum samples and 100 negative serum samples, mostly remnants from lab tests.</p>\n<p>In addition, iSpecimen has been contracted by other federal agencies and private companies for custom COVID-19 collections, which are often complex and complement the more immediate availability of remnant or banked samples.</p>\n<p>\"COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society's ability to contend with future outbreaks of infectious diseases,\" said&nbsp;iSpecimen Founder and CEO,Christopher Ianelli, MD, Ph.D. \"We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they're focusing on.\"</p>\n<p><b>COVID-Related Research</b></p>\n<p>In addition to the work iSpecimen has done with the CDC, iSpecimen has recently supplied hundreds of human biospecimens to ongoing COVID-19 research being conducted by&nbsp;the United Statesmilitary. The specimens, including positive SARS-CoV-2 samples and negative controls, help researchers validate COVID-19 testing platforms, understand fluctuations in patients' antibody levels, monitor contagion among close contacts, and more.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISPC":"iSpecimen Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121185868","content_text":"iSpecimen shares surged more than 140% in early trading.iSpecimen Inc.(Nasdaq: ISPC), an online marketplace forhuman biospecimens, today announced that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.\nThe Company's work on COVID-19 began immediately after the outbreak last year when it began sending serum samples to the U.S. Centers for Disease Control and Prevention to help researchers monitor antibody development for possible guidance on immunity. iSpecimen provided the Centers for Disease Control and Prevention (\"CDC\") with 600 SARS-CoV-2-positive serum samples and 100 negative serum samples, mostly remnants from lab tests.\nIn addition, iSpecimen has been contracted by other federal agencies and private companies for custom COVID-19 collections, which are often complex and complement the more immediate availability of remnant or banked samples.\n\"COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society's ability to contend with future outbreaks of infectious diseases,\" said iSpecimen Founder and CEO,Christopher Ianelli, MD, Ph.D. \"We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they're focusing on.\"\nCOVID-Related Research\nIn addition to the work iSpecimen has done with the CDC, iSpecimen has recently supplied hundreds of human biospecimens to ongoing COVID-19 research being conducted by the United Statesmilitary. The specimens, including positive SARS-CoV-2 samples and negative controls, help researchers validate COVID-19 testing platforms, understand fluctuations in patients' antibody levels, monitor contagion among close contacts, and more.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1069,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}